In various cancer types the PI3K/AKT/mTOR pathway has been implicated in the expression of immunosuppressive chemokines and cytokines [62, 63], expression of the immune suppressive vascular endothelial growth factor (VEGF) [64], reduced tumor CD8+ T cell infiltration [65], expression of immune checkpoints [66–68], and expression of MHC classes I and II (Figure 2) [69, 70]. This evidence concerns the gene MTOR and neoplasm.